GYRE - GYRE THERAPEUTICS, INC.
8.28
0.380 4.589%
Share volume: 100,514
Last Updated: 03-04-2026
Pharmaceutical Products/Pharmaceutical Preparations:
3.72%
PREVIOUS CLOSE
CHG
CHG%
$7.90
0.00
0.00%
View ratios
| Fiscal Date | 03-31-2024 | 06-30-2024 | 09-30-2024 | 12-31-2024 | 03-31-2025 | 06-30-2025 | 09-30-2025 | |
|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
| Report Date | 05-13-2024 | 08-13-2024 | 11-13-2024 | 03-17-2025 | 05-09-2025 | 08-11-2025 | 11-07-2025 | |
| Assets | ||||||||
| Total Assets | 122.010 M | 120.929 M | 125.240 M | 125.406 M | 129.790 M | 152.646 M | 159.384 M | |
| Current Assets | 62.723 M | 53.519 M | 54.809 M | 64.786 M | 68.448 M | 91.285 M | 98.576 M | |
| Inventories | 4.939 M | 5.635 M | 6.379 M | 6.337 M | 7.878 M | 8.861 M | 8.854 M | |
| Other Current Assets | 1.897 M | 1.722 M | 1.513 M | 1.436 M | 0.000 | 0.000 | 0.000 | |
| Short Term Investments | 7.567 M | 9.003 M | 9.226 M | 14.858 M | 14.846 M | 17.874 M | 19.647 M | |
| Total Receivables | 16.745 M | 19.909 M | 20.774 M | 29.153 M | 22.518 M | 25.358 M | 26.800 M | |
| Current Cash | 29.785 M | 16.097 M | 15.866 M | 11.813 M | 15.045 M | 36.491 M | 40.402 M | |
| Total Non-current Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Property Plant Equipment | 23.564 M | 23.672 M | 24.442 M | 23.880 M | 23.518 M | 23.401 M | 23.608 M | |
| Other Assets | 35.723 M | 43.738 M | 45.989 M | 36.740 M | 37.824 M | 37.960 M | 37.200 M | |
| Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | ||||||||
| Total Liabilities and shareholders’ equity | 122.010 M | 120.929 M | 125.240 M | 125.406 M | 129.790 M | 152.646 M | 159.384 M | |
| Total liabilities | 33.239 M | 27.583 M | 26.766 M | 27.004 M | 25.488 M | 23.203 M | 21.969 M | |
| Total current liabilities | 19.486 M | 15.574 M | 14.716 M | 19.516 M | 18.991 M | 16.920 M | 15.913 M | |
| Accounts Payable | 330.000 K | 271.000 K | 303.000 K | 108.000 K | 122.000 K | 71.000 K | 556.000 K | |
| Other liabilities | 13.550 M | 11.817 M | 11.865 M | 6.560 M | 5.592 M | 5.399 M | 5.190 M | |
| Current long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other liabilities | 13.550 M | 11.817 M | 11.865 M | 6.560 M | 5.592 M | 5.399 M | 5.190 M | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 56.640 M | 60.351 M | 63.179 M | 63.319 M | 68.123 M | 92.026 M | 101.920 M | |
| Common stock | 133.284 M | 133.741 M | 134.381 M | 136.271 M | 138.266 M | 161.528 M | 167.225 M | |
| Retained earnings | -78.006 M | -74.478 M | -73.354 M | -73.453 M | -70.755 M | -70.313 M | -66.703 M |